Corporate Overview. June 2018 NASDAQ:FPRX
|
|
- Lily Wilkinson
- 5 years ago
- Views:
Transcription
1 Corporate Overview June 2018 NASDAQ:FPRX
2 Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. These forward-looking statements reflect Five Prime's current beliefs and expectations. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ from these forward-looking statements. Forward-looking statements contained in this presentation include statements about (i) the timing of initiation, progress and scope of clinical trials for our product candidates; (ii) the potential use of our product candidates to treat patients; (iii) the extent of gene amplification and protein overexpression in certain patient populations; (iv) the prevalence and incidence of certain diseases; (v) the timing of the filing of INDs; (vi) the timing of program updates and data disclosures; and (vii) our estimated 2018 net cash used in operating activities and estimated year-end balance of cash, cash equivalents and marketable securities. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Other factors that may cause our actual results to differ from current expectations are discussed in Five Prime's preliminary prospectus supplement relating to the proposed offering and its other filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein, as well as the risks identified in the registration statement and the preliminary prospectus supplement relating to the offering under the heading "Risk Factors." Except as required by law, we assume no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. 2
3 Five Prime in 2018 Value Proposition IND engine that is hard to copy and industry leading for discovery of I-O biologics Expanding pipeline transitioning into latestage development History of value-creating collaborations; eligible to receive additional non-dilutive funding 3
4 The Five Prime Opportunity: Platform and Pipeline to Power Immuno-Oncology Clinical pipeline expected to more than double from 2 to 5 candidates in 2018 Cabiralizumab CSF1R antibody I-O: Phase 2 in 2 nd - line pancreatic Phase 1a/1b in seven tumor settings Including ~60 patients in late-line pancreatic PVNS: Phase 2 ongoing Bemarituzumab FGFR2b antibody Initiation of FIGHT global Ph 1/3 trial in combo with chemo in first-line gastric Discovery platform and capabilities that uniquely position us to identify new I-O targets and therapeutics History of value-creating collaborations FPA150 B7-H4 antibody TIM-3 antibody FPT155 CD80-Fc 4
5 Oncology-Focused Pipeline with Multiple Clinical Candidates Program Collaborator Indications selection Lead Cabiralizumab (FPA008) * CSF-1R antibody Pancreatic cancer (combination with Opdivo and chemo) Multiple tumor settings (combination with Opdivo ) Multiple tumor settings in ADVISE trial (combination with Opdivo ) Pigmented villonodular synovitis (PVNS) IND-enabling Phase 1 activities Phase 1a Phase 1b Phase 2 Phase 3 Bemarituzumab (FPA144) ** FGFR2b antibody FPA150 B7-H4 antibody FPT155 CD80-Fc TIM-3 antibody * I-O antibodies * Novel I-O Biologics FIGHT Phase 1/3 trial (with chemo) in gastric/gej cancer Multiple tumor settings Multiple tumor settings Multiple tumor settings Multiple tumor settings Multiple tumor settings * Partnered with Bristol-Myers Squibb Company (BMS) see Part I Item 1. Collaborations of our most recent Annual Report on Form 10-K for a description of the collaboration arrangement with BMS. ** Partnered with Zai Lab (Shanghai) Co., Ltd. (Zai) see our Current Report on Form 8-K filed with the SEC on December 19, 2017 for a description of the collaboration arrangement with Zai. Excludes investigator-sponsored trials. Clinical development is being conducted exclusively by BMS. 5
6 Cabiralizumab (FPA008) Antibody for Macrophage-Dependent Diseases
7 Cabiralizumab, a Product of the Five Prime Platform, Blocks Survival of Macrophages Cabiralizumab (FPA008) is an antibody to CSF-1R CSF-1 IL-34 Five Prime discovered IL-34, one of the two ligands for CSF-1R that cabiralizumab (FPA008) blocks 7
8 Rationale for Combination I-O Therapy: TAMs and Checkpoints Inhibit T Cell-Mediated Killing Through Different Mechanisms TAM Cabiralizumab blocks CSF-1R & depletes TAMs CD8 T Cell PD-1 TAMs produce factors that inhibit T cells CSF-1R PD-L1 PD-L1/PD-1 suppresses T cells High TAM levels are associated w/poor prognosis in pancreatic and other cancers Tumor Cell 8
9 Exploratory Phase 1 Trial of Cabira + Opdivo in Multiple Tumor Settings PHASE 1a Dose escalation and exploratory expansion Dose escalation cohorts (monotherapy & combination) PHASE 1b Cabiralizumab + Opdivo Completed enrollment end of 2017 Expansion in Selected Tumors Expansion in Pancreatic (n~30) Completed enrollment Q Lung (NSCLC) Lung (NSCLC) Anti-PD-1 Resistant Head & Neck Pancreatic Renal N ~295 patients Study Objectives Safety Objective response rate and duration Survival Baseline and on-treatment biopsies Ovarian Glioblastoma 9
10 Tumor Biopsies Demonstrate that Cabira + Nivo Combination Positively Alters the Tumor Microenvironment* CSF-1R and M2 (immunosuppressive) macrophages decreased in tumors of patients treated with cabiralizumab + nivolumab 1 Change in expression of CSF-1R and macrophage markers (day 28) a Protein Median change from baseline, % Patients with decrease from baseline, % CSF-1R 60 (P = ) 76 CD163 (M2 marker) 43 (P = 0.207) 59 a Increases > 200% from baseline were observed for CSF-1R (n = 5), CD163 (n = 7), and CD68 (n = 6) CD68 (M1 + M2 marker) 16 (P = 0.263) 60 Statistically significant increases in pro-inflammatory markers observed in patients who responded to treatment compared to patients who didn t respond 2 Combination also demonstrated an increase in CD8+ effector cells *ASCO 2018 Carleton et al 1 Tumor biopsies were from patients in all expansion cohorts from the Phase 1a/1b clinical trial, except the cohort of patients with glioblastoma multiforme. 2 Data not shown. 10
11 Significant Unmet Need in Pancreatic Cancer: Current Regimens Have Shown Limited Clinical Benefit Average survival rate for patients with advanced pancreatic cancer % < 3% Onivyde (liposomal irinotecan) Most recent FDA approval; for patients who progressed following gemcitabine-based therapy Onivyde/5-FU/Leucovorin 1 Phase 3 1 YEAR 5 YEAR ORR 7.7% (Phase 2 ORR 7.5%) No demonstrated activity with anti-pd1 therapy in pancreatic cancer Except in the <1-2% of patients who have microsatellite instability-high (MSI) 2 tumors PFS 3.1 months OS 6.1 months Diarrhea, neutropenia, and stomatitis are common Grade 3/4 events 1 Onivyde USPI, 2017; 2 Le DT et al. Science 2017; 357(6349): ; 3 Von Hoff DD et al. N Engl J Med 2013;369: ; 4 American Cancer Society. Pancreatic Cancer. Accessed November 3, 2017; 5 Foley K et al. Cancer Lett 2016;381;
12 Deep and Durable Responses Observed in Late-Line Pancreatic Cancer Progressive disease Treated beyond progressive disease Partial response Efficacy: Durable clinical benefit observed Confirmed ORR = 13% DCR = 16% Days Day Disease control: 5 to 9+ months Heavily pretreated population (average 3 prior lines of therapy) All responders have microsatellite stable (MSS) tumors that do not respond to PD1/L1 therapy Responses accompanied by steep declines in levels of the pancreatic tumor marker CA
13 Reductions in Metastatic Lesions and Tolerable Safety Profile Liver Metastases 58-year-old male: 3 prior chemo regimens Lung Metastases 63-year-old male: 4 prior chemo regimens Safety Profile: Safety profile consistent with nivolumab and cabiralizumab monotherapy Most common TRAEs* were elevations in creatine kinase (CK) and serum liver enzymes (without elevation in bilirubin) Believed to be secondary to cabira s depletion of Kupffer cells (macrophages); reported with other CSF-1R - targeting agents Isolated enzyme elevations were not associated with other clinical sequelae Grade 5 TRAEs** (3 of 229) at a frequency similar to monotherapy PD-1 inhibitors No Grade 5 events in pancreatic cohort * TRAEs treatment related adverse events ** Pneumonitis in a patient with thyroid cancer, and respiratory distress and acute respiratory distress in 2 patients with lung cancer 13
14 BMS Advancing Randomized Phase 2 Trial of Cabiralizumab/Opdivo in 2 nd -Line Pancreatic Cancer (NCT ) 1st Line: Gemcitabine-Based Chemotherapy Trial Arms (2 nd -Line) Arm A: Investigator s Choice of Chemotherapy Gemcitabine/Abraxane or 5-FU/leucovorin/Onivyde Arm B: Cabira + Opdivo N ~160 patients Study Objectives Progression free survival (primary) Objective response rate and duration 1st Line: 5-FU-Based Chemotherapy Arm C: Cabira + Opdivo + gemcitabine + Abraxane Arm D: Cabira + Opdivo + FOLFOX Overall survival rate Safety PK Dosing initiated in January 2018 Study will generate data that could support a front-line or second-line pivotal study 14
15 Advancing Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) A CSF-1-driven locally aggressive tumor of the joint that causes pain and dysfunction Cabiralizumab depletes the macrophages that form the bulk of the tumor Preliminary Phase 2 data demonstrated efficacy with dosing every two weeks, but many patients did not tolerate chronic dosing* Trial amended to optimize therapeutic index with dosing every four weeks 14cm *ASCO 2017 data presentation 15
16 % Change in Tumor from Baseline % Change in Tumor from Baseline Initial Phase 2 Data: Tumor Reductions in Most Patients at 4mg/kg* Dose-dependent responses observed in Phase 2 Most patients had tumor reductions at expansion dose Tolerable safety profile: most frequent AEs were asymptomatic CK elevation, periorbital edema, pruritis Dose-dependent response FPA008 Cohort: 1 mg/kg 2 mg/kg 4 mg/kg Last dose day of Last dose day of patients with PRs PR Study Days Most patients enrolled at the 4 mg/kg dose experienced tumor reduction * ASCO 2017 Sankhala et al. 16
17 Decreases in Pain and Functional Improvements Observed in Phase 2 Decreases in pain and Improvement in Median Ogilvie-Harris Composite Score Reported in Responders and Non-Responders improvement in function important to patients Improved performance of activities of daily living Lowered use of pain medication Preliminary Phase 2 data showed improvements in pain/function in both responders and nonresponders Before treatment * After 5 cabiralizumab doses at 4 mg/kg *29-year-old female with PVNS treated with cabiralizumab 17
18 Phase 2 Trial in PVNS to Inform Possible Pivotal Trial PHASE 2 Dose expansion 4mg/kg Q 2 weeks 30 patients Alternative Dosing Schedule to Improve Tolerability 4mg/kg ~ Q 4 weeks up to 30 patients Study Objectives Objective response Pain Functional improvement Completed Enrollment April 2017 Go/No Go on Pivotal Trial, 2H 2018 Range of motion Tolerability Preliminary Data Presented at ASCO June
19 Bemarituzumab (FPA144) Targeted Immunotherapy for FGFR2b-Overexpressing Tumors
20 Bemarituzumab (FPA144) Was Designed to Recruit Tumor-Killing NK Cells into the Tumor Microenvironment Natural Killer Cell Enhanced ADCC to increase NK cell recruitment FPA144 FGFR2b FGF7, 10, 22 FPA144: antibody specific to FGFR2b splice variant Tumor Cell 20
21 Bemarituzumab Demonstrated Monotherapy Activity in Heavily Pre-treated Patients with FGFR2b+ Gastric Cancer* % Change in Tumor from Baseline Best % Change in Sum of Diameters from Baseline in FGFR2b+ Gastric Cancer ORR (confirmed) = 19% DCR = 57% Safety: No DLTs during dose escalation (MTD not reached) No grade 4 or higher treatment-related AEs Acceptable safety of bema and limited overlapping toxicities allows for chemo combination 6 mg/kg 10 mg/kg 15 mg/kg * ASCO 2017 Catenacci et al + confirmed response per RECIST 21
22 Phase 1/3 FIGHT Pivotal Trial of Bemarituzumab (FPA144) in Front-Line FGFR2b+ Gastric and GEJ Cancer Phase 1 Safety Lead in; any GI cancer Phase 3 Randomized; ~548 selected patients Study Endpoints FPA144 Dose Escalation + FOLFOX6 First patient dosed December 2017 Initiation expected 2H18 FPA144 + FOLFOX6 vs Placebo + FOLFOX6 OS PFS ORR FGFR2b overexpression and FGFR2 gene amplification associated with poor prognosis Select biomarker-positive patients by IHC (tumor sample) or ctdna (blood-based) tests ~10% of patients expected to be biomarker-positive 22
23 FPA150 Targeted Immunotherapy for B7H4-Overexpressing Tumors
24 FPA150: First-In-Class B7-H4 Antibody Designed for Two Mechanisms of Action Blocks a T cell checkpoint pathway expressed on tumor cells Engineered to have enhanced ADCC Phase 1 initiated March 2018 FPA150 B7-H4 is expressed in multiple solid tumors, including breast and gynecologic cancers Triple Negative Breast Cancer Ovarian Cancer 24
25 FPA150 Phase 1 Clinical Trial Testing Monotherapy Against Selected B7-H4 Expressing Tumors PHASE 1a Dose escalation Any solid tumor Phase 1a initiated March 2018 PHASE 1b Expansion; ~30 patients/cohort Breast Cancer Ovarian Cancer Endometrial Cancer Urothelial (Bladder) Cancer Additional cohorts TBD based on emerging data IHC assay to be used to select B7-H4 expressing tumors in Phase 1b Evaluating several I-O and chemo combination strategies to implement depending on Phase 1b monotherapy data Study Objectives Safety Objective response rate and duration Survival Baseline and on-treatment biopsies 25
26 Research and Preclinical Pipeline
27 FPT155: First-In-Class CD80-Fc Fusion Protein Engineered to Activate T Cells Through Multiple Pathways Normal T cell activation via CD80 Antigen presenting cell CD80 CD28 T cell (+) signal FPT155 uses the binding interactions of soluble CD80 to: Directly engage CD28 to enhance its co-stimulatory activity (without super agonism) Block CTLA-4 from competing for endogenous CD80, allowing CD28 signaling to prevail in T cell activation MHC TCR CD80 extracellular domain CD80 is a co-stimulatory molecule expressed on antigen presenting cells IND or equivalent planned 2H18 Fc 27
28 IND Engine: Unique Platform Generating Novel Therapeutics Comprehensive Libraries of Extracellular Proteins Proprietary Screens Protein Therapeutics Secreted Factors Advanced Into Clinical Development cabiralizumab (anti-csf-1r) Cell-based Screens Antibodies bemarituzumab (anti-fgfr2b) Cell Surface Receptors/Ligands In Vivo Screens Soluble Receptors Ligand Traps FPA150 (anti-b7h4) Anti-TIM-3 Soluble Extracellular Domains Receptor-Ligand Matching 28
29 Cash, Guidance and 2018 News and Milestones
30 Cash and Shares Outstanding Cash, cash equivalents & marketable securities Shares outstanding Estimated cash, cash equivalents & marketable securities, EOY 2018 FY 2018 estimated net cash used in operating activities $389.4 million as of March 31, million as of March 31, 2018 ~ $250 million < $135 million 30
31 2018 Five Prime News Flow and Milestones Cabiralizumab Pancreatic Cancer BMS initiated randomized Phase 2 trial (2 nd -line pancreatic) combo with Opdivo and chemo Treating additional 35 late-line pancreatic patients with cabira+opdivo and complete biomarker analysis Pharmacodynamics and genomic profiling data abstract at ASCO 2018 Cabira/Opdivo in Other Tumor Settings Completed Phase 1b enrollment YE17; anticipate program updates in 2H18 PVNS (Monotherapy) Enrolling additional patients with flexible q4 week schedule; decide on pivotal trial by EOY18 FPA150 (B7-H4 Antibody) Initiated Phase 1 March 2018 Oral Presentation at AACR 2018 New Programs Bemarituzumab (FPA144) Gastric/GEJ Cancer Complete Phase 1 portion of FIGHT chemo combo trial Initiate randomized, global Phase 3 portion 2H18 Completed enrollment in Japan Phase 1 trial FIGHT trial-in-progress abstract at ASCO 2018 FPT155 (CD80-Fc) IND or equivalent in 2H18 Anti-TIM-3 Phase 1 initiated 31
32 Thank you NASDAQ:FPRX
Leerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationCorporate Overview. March 2018 NASDAQ:FPRX
Corporate Overview March 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationCorporate Overview. September 2018 NASDAQ:FPRX
Corporate Overview September 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationCorporate Overview. June 2017 NASDAQ:FPRX
Corporate Overview June 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Antitumor Activity and Safety of FPA144, an ADCCenhanced, FGFR2b Isoform-Selective Monoclonal Antibody, in Patients with FGFR2b + Gastric Cancer and Advanced Solid Tumors Jeeyun Lee 1, Johanna Bendell
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationCiti s 13 th Annual Biotech Conference September 5, 2018
Citi s 13 th Annual Biotech Conference September 5, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationBank of America Merrill Lynch 2018 Health Care Conference. Reinventing Therapeutic Antibodies for the Treatment of Cancer
Bank of America Merrill Lynch 2018 Health Care Conference Reinventing Therapeutic Antibodies for the Treatment of Cancer May 17, 2018 1 Forward Looking Statements Special Note Regarding Forward-Looking
More informationDr Wainberg has no relationships related to this presentation to disclose
O4 First-in-Human Phase Dose Escalation and Expansion of a Novel Combination, Anti CSF- Receptor (cabiralizumab) Plus Anti PD- (nivolumab), in Patients With Advanced Solid Tumors Zev A. Wainberg, Sarina
More information2016 Year-End Results and Conference Call. March 14, 2017
2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationReimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 Forward-Looking
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationSyndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationCorporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018
Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO Forward-Looking Statements This
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationInvestor Meetings October 2018
Investor Meetings October 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 1Q 2018 EARNINGS PRESENTATION MAY 2018 1 Forward-looking statements disclosure This presentation contains
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2017 EARNINGS PRESENTATION MARCH 2018 1 Forward-looking statements disclosure This presentation contains
More informationNewLink Genetics Corporation
Stifel Healthcare Conference Presentation NewLink Genetics Corporation NASDAQ: NLNK November 13, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationArray BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018
Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationCalithera Biosciences. January 2019
Calithera Biosciences January 2019 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the
More informationA Fully Integrated Cancer Company.
A Fully Integrated Cancer Company. Jefferies Global Healthcare Conference June 3, 2014 Robert Mulroy, President and CEO Forward Looking Statements To the extent that statements contained in this presentation
More informationJefferies 2018 Healthcare Conference. June 6, 2018
Jefferies 2018 Healthcare Conference z June 6, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of ongoing
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationCalithera Biosciences
Calithera Biosciences March 2019 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the Private
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationCowen Health Care Conference
Cowen Health Care Conference Dr. Fouad Namouni Head of Medical March 7, 2016 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute
More informationAttached from the following page is the press release made by BMS for your information.
June 2, 2015 Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial (PRINCETON, NJ, May
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationThe Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018
The Next Generation of Immunotherapy Platforms 36 th Annual J.P. Morgan Healthcare Conference January 2018 Forward-Looking Statements This presentation contains certain forward-looking information about
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationOMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationCalithera Biosciences. September 2018
Calithera Biosciences September 2018 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More information2019 ASCO-SITC. Nektar Therapeutics Investor & Analyst Call. March 1, 2019
Nektar Therapeutics Investor & Analyst Call March 1, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More information